Business ❯ Mergers and Acquisitions

Pharmaceutical Industry

Investment Competition Biotechnology Drug Development Eli Lilly Regulatory Approval Cancer Treatment Cancer Treatments Biotech Companies Recent Acquisitions Orchard Therapeutics Acquisition Ophthalmology Genetic Research Genetic Testing Genomics Vaccine Development Obesity Drugs Startup Companies Market Competition Perrigo Co Corporate Acquisitions Rare Diseases Drugs Rare Disease Drugs AI in Drug Development

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

The cash offer centers on tovorafenib for pediatric low‑grade glioma to advance Servier’s precision oncology strategy.

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

Lilly Strikes Up to $1.12 Billion Pact With Seamless Therapeutics for Hearing‑Loss Gene Editing

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

Regeneron to Acquire 23andMe for $256 Million Following Bankruptcy Auction